Investment Strategies in Emerging Biosensor Technologies (IV/IV)
With the market projected to surpass $49 billion by 2030, the success of companies like Biolinq and Delta Diagnostics highlights the importance of interdisciplinary collaboration, market-driven innovation, and strategic investments. Investors should prioritize diversified portfolios focusing on high-growth segments such as AI-enabled and nanomaterial-based biosensors, while ensuring scalability, regulatory compliance, and robust intellectual property strategies […]